Paper1925862
Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research.
Ténière P and 3 others. Surg Gynecol Obstet, 1991. Cited by 237 papers, by iCite.
Cite this record
ConductScience Library. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Papers, record 1925862. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1925862
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research.
- PubMed
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Squamous Cell | Major topic |
| Esophageal Neoplasms | Major topic |
| Radioisotope Teletherapy | Major topic |
| Radiotherapy, High-Energy | Major topic |
| Combined Modality Therapy | |
| Esophagectomy | |
| Female | |
| Humans | |
| Life Tables | |
| Male | |
| Middle Aged |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01745107 | Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; | Background | ClinicalTrials.gov | |
| NCT02279134 | Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma | Background | ClinicalTrials.gov |
Cited by92
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 237 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42523699 | Postoperative radiotherapy for resected esophageal squamous cell carcinoma: a systematic review and meta-analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42523699 | PubMed |
| 41987784 | Retrospective analysis of postoperative adjuvant therapy and survival in T4 esophageal squamous cell carcinoma: a dual-cohort study using SEER and Chinese multicenter data. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/41987784 | PubMed |
| 41646489 | German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus-version 4.0. | ESMO Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/41646489 | PubMed |
| 41531940 | Postoperative chemoradiotherapy for esophageal squamous cell Carcinoma: Results from ESO-Shanghai 17 and joint analyses for phase II clinical trials. | Clin Transl Radiat Oncol | 2026 | https://conductscience.org/library/papers/41531940 | PubMed |
| 40061535 | Radiation therapy does not improve survival in patients who are upstaged after esophagectomy for clinical early-stage esophageal adenocarcinoma. | JTCVS Open | 2025 | https://conductscience.org/library/papers/40061535 | PubMed |
| 39259654 | Postoperative Radiotherapy in Curatively Resected Esophageal Squamous Cell Carcinoma With Occult Recurrent Laryngeal Nerve Lymph Node Metastasis. | Cancer Control | 2024 | https://conductscience.org/library/papers/39259654 | PubMed |
| 38366184 | ASO Author Reflections: The Challenging Journey from cCR to pCR After Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma. | Ann Surg Oncol | 2024 | https://conductscience.org/library/papers/38366184 | PubMed |
| 36750858 | Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9). | Radiat Oncol | 2023 | https://conductscience.org/library/papers/36750858 | PubMed |
| 36497360 | Effect of Adjuvant Radiation Dose on Survival in Patients with Esophageal Squamous Cell Carcinoma. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36497360 | PubMed |
| 36318394 | [Esophageal Cancer]. | Wien Med Wochenschr | 2023 | https://conductscience.org/library/papers/36318394 | PubMed |
| 35847922 | Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial. | Front Oncol | 2022 | https://conductscience.org/library/papers/35847922 | PubMed |
| 35053594 | Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35053594 | PubMed |
| 34790368 | Preliminary evaluation of postoperative radiotherapy with small T-shaped field in thoracic esophageal squamous cell carcinoma. | J Gastrointest Oncol | 2021 | https://conductscience.org/library/papers/34790368 | PubMed |
| 34423171 | Shifting sands: the role of radiotherapy for patients with gastric and gastroesophageal adenocarcinoma. | Transl Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/34423171 | PubMed |
| 34309117 | Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. | Oncologist | 2021 | https://conductscience.org/library/papers/34309117 | PubMed |
| 34295813 | The Prognosis and Feasibility of Extensive Clinical Target Volume in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial. | Front Oncol | 2021 | https://conductscience.org/library/papers/34295813 | PubMed |
| 33976727 | Adjuvant Radiotherapy of Involved Field versus Elective Lymph Node in Patients with Operable Esophageal Squamous Cell Cancer: A Single Institution Prospective Randomized Controlled Study. | J Cancer | 2021 | https://conductscience.org/library/papers/33976727 | PubMed |
| 33969465 | Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis. | Ann Surg Oncol | 2021 | https://conductscience.org/library/papers/33969465 | PubMed |
| 33937059 | Pattern of Recurrence in 428 Patients With Thoracic Esophageal Squamous Cell Carcinoma After Radical Surgery and Its Implication in Postoperative Radiotherapeutic Clinical Target Volume. | Front Oncol | 2021 | https://conductscience.org/library/papers/33937059 | PubMed |
| 33889204 | Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. | Ecancermedicalscience | 2021 | https://conductscience.org/library/papers/33889204 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1925862
GET https://conductscience.org/api/papers/v1/1925862/cited_by?page=2